文献速递肝病

接种疫苗后感染COVID-19与肝硬化患者死亡率降低相关

Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis.
PubMed 文献 · Hepatology · 2022-02-22

该回顾性队列研究纳入美国退伍军人肝硬化患者,比较接种疫苗后感染COVID-19者与未接种感染者的死亡率。在1:2倾向性匹配队列中,接种后感染与死亡风险降低相关(aHR 0.21,95%CI 0.11-0.42),完全接种和部分接种后感染均观察到该关联。

要点

  • 肝硬化患者接种疫苗后仍可发生突破性COVID-19感染。
  • 接种后感染与死亡风险降低相关(aHR 0.21,95%CI 0.11-0.42)。
  • 完全接种和部分接种后感染均观察到死亡风险降低。

核心结论

  • 肝硬化患者完全或部分接种疫苗后仍可发生突破性COVID-19,但这些感染与死亡率降低相关。

研究设计与样本

  • 回顾性队列研究,纳入美国退伍军人肝硬化合并接种后或未接种COVID-19患者。
  • 完全接种定义为第二剂辉瑞BNT162b2、莫德纳1273-mRNA或单剂杨森Ad.26.COV2.S疫苗后14天诊断COVID-19。
  • 部分接种定义为任何疫苗第一剂后7天但未完成完全接种时诊断COVID-19。
  • 共识别3242例未接种和254例接种后COVID-19肝硬化患者(完全接种后82例,部分接种后172例)。
  • 多变量分析采用1:2倾向性匹配队列,包括接种组254例和未接种组508例。

主要发现

  • 接种后COVID-19与死亡风险降低相关(aHR 0.21,95%CI 0.11-0.42)。
  • 完全接种后感染与死亡风险降低相关(aHR 0.22,95%CI 0.08-0.63)。
  • 部分接种后感染与死亡风险降低相关(aHR 0.19,95%CI 0.07-0.54)。
  • 接种1273-mRNA后感染与死亡风险降低相关(aHR 0.12,95%CI 0.04-0.37)。
  • 接种BNT162b2后感染与死亡风险降低相关(aHR 0.27,95%CI 0.10-0.71)。

关键数值与推荐

  • 代偿期肝硬化患者中接种后感染与死亡风险降低相关(aHR 0.19,95%CI 0.08-0.45)。
  • 失代偿期肝硬化患者中接种后感染与死亡风险降低相关(aHR 0.27,95%CI 0.08-0.90)。
  • 限制在疫苗可及后感染参与者的敏感性分析结果一致。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients develop breakthrough COVID-19 infection despite vaccination. The aim of this study was to identify outcomes in patients with cirrhosis who developed postvaccination COVID-19. METHODS: We performed a retrospective cohort study among US veterans with cirrhosis and postvaccination or unvaccinated COVID-19. Patients were considered fully vaccinated if COVID-19 was diagnosed 14 days after the second dose of either the Pfizer BNT162b2, the Moderna 1273-mRNA, or the single-dose Janssen Ad.26.COV2.S vaccines and partially vaccinated if COVID-19 was diagnosed 7 days after the first dose of any vaccine but prior to full vaccination. We investigated the association of postvaccination COVID-19 with mortality. RESULTS: We identified 3242 unvaccinated and 254 postvaccination COVID-19 patients with cirrhosis (82 after full and 172 after partial vaccination). In a multivariable analysis of a 1:2 propensity-matched cohort including vaccinated (n = 254) and unvaccinated (n = 508) participants, postvaccination COVID-19 was associated with reduced risk of death (adjusted HR [aHR], 0.21; 95% CI, 0.11-0.42). The reduction was observed after both full (aHR, 0.22; 95% CI, 0.08-0.63) and partial (aHR, 0.19; 95% CI, 0.07-0.54) vaccination, following the 1273-mRNA (aHR, 0.12; 95% CI 0.04-0.37) and BNT162b2 (aHR, 0.27; 95% CI, 0.10-0.71) vaccines and among patients with compensated (aHR, 0.19; 95% CI, 0.08-0.45) and decompensated (aHR, 0.27; 95% CI, 0.08-0.90) cirrhosis. Findings were consistent in a sensitivity analysis restricted to participants who developed COVID-19 after vaccine availability. CONCLUSIONS: Though patients with cirrhosis can develop breakthrough COVID-19 after full or partial vaccination, these infections are associated with reduced mortality.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. John BV, Deng Y, Schwartz KB, et al. Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology. 2022. PMID: 35023206. doi:10.1002/hep.32337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。